Cxbladder

Greater confidence in the risk stratification and surveillance of bladder cancer

Cxbladder - Greater confidence in the risk stratification and surveillance of bladder cancer

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help clinicians improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency. 

The Cxbladder suite: 

  • Enables reliable risk stratification and rule out, to reduce the number of unnecessary cystoscopies and spare low risk patients the discomfort, anxiety and risks of an invasive procedure, while prioritizing those who require immediate care.
  • Helps clinicians confirm a diagnosis when other tests and procedures yield ambiguous results, reducing the likelihood of a missed tumor.
  • Offers a non-invasive surveillance alternative that can reduce the burden of cystoscopy, improving patient comfort and compliance.


Cxbladder works at a molecular level, analyzing five biomarker genes to rule out disease.

  • Accurate: Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results.​ The test works at a molecular level, analyzing biomarker genes to help rule out urothelial cancer.​
  • Clinically proven: Proven performance in over 25 peer-reviewed publications for hematuria evaluation and surveillance. Cxbladder has been used by over 5,000 US urologists in more than 100,000 patients. In New Zealand the test is available to 70% of the population via public healthcare, and to all other residents through an e-commerce portal.
  • Non-invasive and easy-to-use: Cxbladder's non-invasive urine sampling system, with the option of in-home sample collection, is easy for both clinical teams and patients to use.

Hematuria Evaluation

Cxbladder Triage

As a frontline diagnostic to support risk stratification, Cxbladder Triage is optimized to help de-intensify clinical work-up in microhematuria patients with a low probability Triage test result, reducing the need for referral and invasive procedures, while prioritizing those who require further investigation. Cxbladder Triage is now included in the American Urological Association (AUA) Microhematuria Guideline, the first and only urine-based genomic biomarker test recommended with supporting Level A Evidence.*​

Triage supports a new model for clinical practice and resource utilisation. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.

* Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490

Cxbladder Detect

Cxbladder Detect is designed to improve practice workflow and efficiency in urological care, while giving patients the best experience possible. The test is optimized for the risk stratification of patients presenting with microhematuria and helps to de-intensify clinical work-up in in those with a low probability Detect test result.

Detect is a reliable adjunct when other tests are inconclusive. The test resolves atypical cytology and equivocal cystoscopy. 

Cxbladder Triage Plus

Cxbladder Triage Plus is a next generation Cxbladder test that combines an analysis of mRNA and DNA markers to further improve clinical utility and efficiency. As a single test for hematuria evaluation, Triage Plus is optimized for the risk stratification of patients presenting with microhematuria. 

The commercial launch of Cxbladder Triage Plus is expected soon.

 

Bladder Cancer Surveillance

Cxbladder Monitor

Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients being monitored for recurrent non-muscle invasive bladder cancer (NMIBC). In suitable cases Monitor can alternate with cystoscopy to de-intensify surveillance. The test can replace cystoscopy in patients with no recurrence long term after shared decision between doctor and patient.

With the option of in-home sampling, Monitor improves patient comfort and compliance with cancer surveillance and management regimes. 

Cxbladder is available in the following countries

The Americas

  • United States 
  • Argentina
  • Uruguay
  • Venezuela

 

Asia Pacific 

  • Australia 
  • New Zealand 
  • Singapore
  • Hong Kong 
  • Taiwan
  • Thailand
  • Vietnam 
  • Philippines 
  • Malaysia
  • Indonesia 
  • Brunei 

 

Europe & the Middle East

  • Israel